ASCO® GI 2025 Summary: Meta-Analysis of Phase II/III RCTs to Evaluate the Incidence of HTN, Proteinuria, Hemorrhage, and VTE in GI Cancer Patients Treated With Fruquintinib | VuMedi

Find latest Colon Cancer videos · 300+ videos

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

10 seconds

Playback speed

This video is featured in the Insights from 2025 ASCO® GI Annual Meeting

Insights from 2025 ASCO® GI Annual Meeting

ASCO® GI 2025 Summary: Meta-Analysis of Phase II/III RCTs to Evaluate the Incidence of HTN, Proteinuria, Hemorrhage, and VTE in GI Cancer Patients Treated With Fruquintinib

By Insights from 2025 ASCO® GI Annual Meeting FEATURING Kyaw Thein

By Insights from 2025 ASCO® GI Annual Meeting FEATURING Kyaw Thein

122 views

February 12, 2025

Comments 0

Login to view comments. Click here to Login